UK markets open in 2 hours
NIKKEI 225
38,226.51 -47.54 (-0.12%) HANG SENG
18,155.28 +392.25 (+2.21%) CRUDE OIL
79.52 +0.52 (+0.66%) GOLD FUTURES
2,327.70 +16.70 (+0.72%) DOW
37,903.29 +87.37 (+0.23%) Bitcoin GBP
45,733.92 -2,290.04 (-4.77%)
BioInvent International AB (BIX.BE)
Berlin - Berlin Delayed price. Currency in EUR
Add to watchlist
At close: 07:46PM CEST
| Previous close | 0.1738 |
| Open | 0.1748 |
| Bid | 0.1384 x 1190000 |
| Ask | 0.2090 x 1190000 |
| Day's range | 0.1714 - 4.3450 |
| 52-week range | 0.1714 - 4.3450 |
| Volume | |
| Avg. volume | 41 |
| Market cap | N/A |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | 24 Apr 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
PR NewswireCASI Pharmaceuticals Report Positive Interim Phase 1 Data For BI-1206 In The Treatment Of Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma In China
CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a biopharmaceutical company specializing in the development and commercialization of innovative therapeutic and pharmaceutical products, and BioInvent International AB ("BioInvent") (Nasdaq Stockholm: BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, today announced preliminary encouraging efficacy data for BI-1206 in combination with rituximab in patients
© 2024 Yahoo. All rights reserved.